# Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

> **NCT00304031** · PHASE3 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 1173 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** Concurrent temozolomide
- **RADIATION:** Concurrent radiation therapy
- **DRUG:** 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle
- **DRUG:** 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle

## Key facts

- **NCT ID:** NCT00304031
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2011-02
- **Final completion:** 2016-12
- **Target enrollment:** 1173 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00304031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00304031, "Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00304031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*